Sublimity Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Sublimity Therapeutics Ltd(Sublimity) formerly known as Sigmoid Pharma Ltd, focuses on the development of therapeutics for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The companys product portfolio includes cyclosporine, oral vaccines, oral peptides and formulations. Sublimity develops therapies by using its proprietary technology, SmPill (single-multiple pill) for the treatment of crohns disease, graft versus host disease, psoriasis, diarrhoea, helicobacter pylori, colon cancer, coeliac disease and inflammatory bowel. It works in collaboration with the Advanced Immunization Technologies Consortium, Irish Drug Delivery Network and TRANSINT Consortium among others. The company operates GMP manufacturing facility in the Invent Centre. Sublimity is headquartered in Dublin, Ireland.

Sublimity Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Sublimity Therapeutics Raises USD64 Million in Venture Financing 10
Sigmoid Pharma Raises US$3.8 Million In Venture Financing 12
Licensing Agreements 13
Dr. Falk Pharma Enters into Licensing Agreement with Sigmoid Pharma 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Equity Offering 15
Sigmoid Pharma Raises USD6.3 Million in Private Placement 15
Acquisition 16
Sigmoid Pharma Acquires Freund Pharmatec 16
Sublimity Therapeutics Ltd - Key Competitors 17
Sublimity Therapeutics Ltd - Key Employees 18
Sublimity Therapeutics Ltd - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Mar 06, 2017: Sigmoid Pharma Announces the Appointment of Lorin K. Johnson, PhD as a Non-Executive Director 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List Of Tables


Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sublimity Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sublimity Therapeutics Raises USD64 Million in Venture Financing 10
Sigmoid Pharma Raises US$3.8 Million In Venture Financing 12
Dr. Falk Pharma Enters into Licensing Agreement with Sigmoid Pharma 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Sigmoid Pharma Raises USD6.3 Million in Private Placement 15
Sigmoid Pharma Acquires Freund Pharmatec 16
Sublimity Therapeutics Ltd, Key Competitors 17
Sublimity Therapeutics Ltd, Key Employees 18
Sublimity Therapeutics Ltd, Subsidiaries 19

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

Sublimity Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sublimity Therapeutics Ltd(Sublimity) formerly known as Sigmoid Pharma Ltd, focuses on the development of therapeutics for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The companys product portfolio

USD 250 View Report

Sublimity Therapeutics Ltd - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sublimity Therapeutics Ltd(Sublimity) formerly known as Sigmoid Pharma Ltd, focuses on the development of therapeutics for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The companys product portfolio

USD 250 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available